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Lugt, A. Van Dongen, and E. Zini
Background: The European Veterinary Renal Pathology Service (EVRPS) is the first Web-based registry for canine renal
biopsy specimens in Europe.
Hypothesis/Objectives: The aim was to verify whether differences exist between the clinical and laboratory presentation of
dogs with nephropathy according to renal pathological findings, as defined by light and electron microscopy of renal biopsy
specimens submitted to EVRPS.
Animals: Renal biopsy specimens of dogs were collected from the archive of the service (n = 254). Cases were included if
both light and electron microscopy were available (n = 162).
Methods: Renal biopsy specimens were classified based on the morphological diagnoses. Thereafter, they were grouped
into 3 disease categories, including immune-complex-mediated glomerulonephritis (ICGN), non-immune-complex-mediated
GN (non-ICGN), and renal lesions not otherwise specified (RL-NOS). Differences among morphological diagnoses and
among disease categories were investigated for clinical and laboratory variables.
Results: Serum albumin concentration was lower in dogs with ICGN than in those with non-ICGN (P = 0.006) or RL-
NOS (P = 0.000), and the urine protein-to-creatinine ratio (UPC) was significantly higher in ICGN than in the other 2 dis-
ease categories. Regarding morphological diagnoses, albumin was significantly lower in amyloidosis (AMY) and membranous
(MGN), membranoproliferative (MPGN) or mixed glomerulonephritis (MixGN) than in minimal change disease, primary
(FSGS I) or secondary (FSGS II) focal and segmental glomerulosclerosis and juvenile nephropathies (JN). The UPC was
higher in MPGN than in FSGS I and FSGS II.
Conclusions and clinical importance: Dogs with ICGN, in particular MPGN, had higher protein loss than those with non-
ICGN or RL-NOS, leading to more severe hypoalbuminemia. Clinical and laboratory differentiation among dogs with the
different morphological diagnoses and among dogs with different disease categories was difficult due to overlapping results.
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To date, the EVRPS serves European veterinarians
providing renal pathology consultations (LA, AVD)
and detailed diagnoses including light microscopy
(LM), immunofluorescence (IF), and transmission elec-
tron microscopy (TEM) in a short turnaround time. A
diagnosis is obtained by the consensus of 3 patholo-
gists with renal pathology experience (LA, SB, and
JVL). The EVRPS also represents the first continental
registry to record pathological diagnosis, as well as
clinicopathologic data of dogs undergoing RBs. Regis-
tries represent important tools, providing epidemiologi-
cal data or characteristic findings of various diseases,
and are widely used in human medicine. In 2013, the
largest series of RBs in dogs, obtained from 501 dogs
living in North America, was reported.1 A wide array
of renal diseases was described in dogs, but clinical
and laboratory findings were not provided. A collec-
tion of clinical, laboratory, and pathological data from
dogs with renal disease is difficult for many reasons.
First, RBs are not usually included in the diagnostic
evaluation in clinical practice. Furthermore, it is now
recognized that complete evaluation of RBs requires
LM and TEM examination combined with IF.2,3
Unfortunately, TEM facilities are not always available
in private and academic veterinary diagnostic center
and cost may represent a limiting factor. Therefore,
comprehensive surveys are difficult to perform and
require excessively long time periods and multicenter
investigations.
The aims of our report from EVRPS were to charac-
terize the clinical and laboratory presentation of dogs
with suspected renal disease that had RBs submitted to
the EVRPS, to classify the RBs according to LM and
TEM examination, and to identify possible differences
between clinical and laboratory findings based on renal
morphological diagnoses and renal disease categories.
The survey included dogs living in Europe.
Materials and Methods
Case selection
Renal biopsy specimens submitted between 2008 and 2015 were
collected from the archive of the UVNS/EVRPS. Although stan-
dard RB evaluation consists of LM, IF, and TEM, the presence of
LM and TEM reports was the sole inclusion criterion for selec-
tion. The IF results were considered to complement the diagnosis
but were not included in the data analysis. For all cases, clinical
and laboratory variables were retrieved from signalment, history,
hematology and serum biochemical profile results, and urinalysis.
All data were provided by the referring veterinarians.
Processing of RBs
All RBs were routinely processed for LM and TEM examina-
tion.4 Specimens for LM were sectioned at 3 lm thickness and
stained with hematoxylin and eosin, periodic acid-Schiff, Masson’s
trichrome, and periodic acid-methenamine silver. Congo red stain-
ing was performed on 8- to 10-lm sections if amyloid was sus-
pected, to confirm the diagnosis. For TEM, tissues were fixed in
chilled 3% buffered glutaraldehyde and processed according to
standard procedures.4
Evaluation of RBs
The evaluation and classification of renal lesions were based on
diagnostic criteria developed by WSAVA-RSSG.4 Transmission
electron microscopy was used as the gold standard method for
immune-complex detection. The RBs were analyzed individually
and then grouped into 3 disease categories: (1) immune-complex-
mediated glomerulonephritis (ICGN) when glomerular immune-
complex deposits were identified by TEM, including membranous
GN (MGN), membranoproliferative GN (MPGN), mixed GN
(MixGN) and focal and segmental glomerulosclerosis pattern
secondary to immune-complex deposits (FSGS II); (2) non-
immune-complex-mediated GN (non-ICGN) when glomerular
immune-complex deposits were not identified by TEM, including
minimal change disease (MCD), amyloidosis (AMY), focal and
segmental glomerulosclerosis pattern not associated with other
glomerular diseases (FSGS I); and, (3) renal lesions not otherwise
specified (RL-NOS), including juvenile nephropathies (JN) and
miscellaneous diseases (MD). Dogs without evident lesions on
TEM were arbitrarily included in the latter group.
Statistical Analysis
Analyses were performed by a commercial softwarea to detect
possible associations between clinical or laboratory findings and
pathological results. Initially, the analysis was conducted compar-
ing all morphological diagnoses, and it subsequently was recon-
ducted considering the 3 disease categories. The following
variables collected from the signalment and history were used in
the analysis: age at diagnosis, sex (male, female), disease onset
(acute, chronic), body weight and appetite (decreased, increased),
anorexia, vomiting, polyuria and polydipsia, lethargy, previous
episodes of urinary tract infection (UTI), subcutaneous edema,
ascites, hypoalbuminemia, gross hematuria, and proteinuria (pre-
sent, absent). Furthermore, laboratory results were considered in
the analysis if recorded within 1 month before biopsy, including
hematocrit; leukocyte count; serum albumin, total protein, crea-
tinine, urea nitrogen, sodium, potassium, total calcium, phospho-
rus and antithrombin III concentrations; and urinalysis including
color, specific gravity, pH, glucosuria, erythrocytes, leukocytes,
and UPC.
In particular, contingency tables were prepared for each of the
aforementioned variables, and the Pearson chi-square test was per-
formed to assess their possible association with morphological
diagnoses and disease categories. When appropriate, Fisher’s exact
test was used for 292 contingency tables.
For continuous variables, a Shapiro-Wilk test was performed to
assess whether or not the data were normally distributed.
Kruskal-Wallis or analysis of variance (ANOVA) tests were
performed to compare means among the different morphological
diagnoses and disease categories. When a significant variation
among groups occurred, posthoc analysis was performed with
Mann-Whitney, Bonferroni, or Dunnett tests, based on data distri-
bution and homoscedasticity assessment. Significance was set at
P ≤ 0.05 for all tests except for the Mann-Whitney test for which
(based on the number of possible paired contrasts) the significance
threshold was set at P ≤ 0.016 for disease categories and at
P ≤ 0.001 for morphological diagnoses to decrease the family-wise
error rate (FWER) in multiple comparisons.
When only 2 groups were compared, the independent-samples
t-test or the Mann-Whitney test was performed according to data
distribution. Significance was set at P ≤ 0.05 for both tests.
Finally, Cohen’s kappa was calculated to assess the level of
agreement between LM and TEM in the disease categories and
morphological diagnoses assignment. Results were evaluated as
previously described.5
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Results
Cases
Over a period of 7 years, 254 RBs were sent to the
UVNS/EVRPS. Ninety-two samples were excluded
because either LM or TEM was missing. Veterinarians
from different European countries used the service; RBs
coming from Sweden were most frequent (n = 43), fol-
lowed by the United Kingdom (n = 41), the Nether-
lands (n = 33), Belgium (n = 8), Norway (n = 7),
Finland (n = 6), France (n = 6), Germany (n = 6), Italy
(n = 4), Ireland (n = 3), Hungary (n = 2), Switzerland
(n = 2), and Spain (n = 1). The proportion of cases for
which the different data were available varied widely
within the study population, ranging from 6.8% (for
antithrombin III activity) to 100% (for vomiting). Com-
plete details are provided in Tables 2–5 and S1 to S4.
Golden Retrievers (n = 11), Labrador Retrievers
(n = 9), and Schapendoes (n = 8) were the most com-
monly represented breeds. Females (52%) slightly out-
numbered males (48%). The median age at presentation
was 74 months (6.2 years), with 54.3% of dogs being
<7 years old.
Morphological Diagnosis
By LM, 53 (32.7%) renal biopsy specimens were classi-
fied as FSGS I (Fig 1A,B), 28 (17.3%) as MGN (Fig 1C,
D), 26 (16%) as MPGN (Fig 1E,F), 11 (6.8%) as AMY
(Fig 1G, H), 4 (2.5%) as JN, 2 (1.2%) as MixGN, and 1
(0.6%) as MCD; 21 (13%) dogs had MD and 16 (9.9%)
showed no abnormalities. By TEM, the definitive diagno-
sis changed in 71 dogs (Table 1). The final diagnosis did
not change for dogs identified by LM as AMY, MCD,
MixGN, and JN. Interestingly, none of the dogs had
FSGS II based on LM, whereas based on TEM it was
diagnosed in 19 cases. Cohen’s kappa was 0.494.
Age significantly differed among morphological diag-
noses (P = 0.002); in particular, dogs with JN were
younger than dogs with MPGN (P = 0.001) and those
with FSGS I (P = 0.000; Table 2).
Considering historical data, significant differences in
proportions among groups were found for the detec-
tion of UTI (P = 0.040) and ascites (P = 0.014;
Table 3). Indeed, UTI was less frequent in dogs
with MPGN and MixGN; ascites and abdominal dis-
tension were less frequent in dogs with MPGN and
FSGS I.
Concerning hematology and serum biochemical pro-
files, significant differences in proportions among
groups were found for alterations of serum concentra-
tions of albumin and total protein (P = 0.000 and
P = 0.001; Table 3). Hypoalbuminemia and hypopro-
teinemia were more common in dogs with AMY,
MGN, MPGN, and MixGN. Significant differences
among groups were present for serum concentrations of
albumin (P = 0.000), total protein (P = 0.001), crea-
tinine (P = 0.013), urea nitrogen (P = 0.021), and phos-
phorus (P = 0.012; Table 2). In particular, serum
albumin concentration was lower in dogs with AMY,
MPGN, and MixGN than in dogs with FSGS I, FSGS
II, and JN (P-values of paired comparisons from 0.000
to 0.001), and in dogs with MGN than in dogs with
MCD, MixGN, and JN (P = 0.000 for all compar-
isons). Total protein concentrations were lower in dogs
with AMY or MGN than in dogs with FSGS II
(P = 0.040 and P = 0.007, respectively). Serum crea-
tinine concentration was lower in dogs with MCD than
in dogs with MPGN (P = 0.000). Concerning urea
nitrogen concentration, no significant result was
obtained for paired comparisons. Serum phosphorus
concentration was higher in dogs with MD than in dogs
with FSGS I (P = 0.001).
Regarding urinalysis, significant differences were
found among groups for the presence of erythrocytes
(P = 0.009) and proteinuria (P = 0.000; Table 3). Ery-
throcytes were less commonly observed in the urine of
dogs with FSGS I and more commonly in the urine of
dogs with MPGN and MixGN. Proteinuria was slightly
less common in dogs with FSGS II and frequently
absent in those with JN; in the latter, approximately
half had no proteinuria. Mean UPC and urine specific
gravity were significantly different among groups
(P = 0.017 and P = 0.000, respectively; Table 2). In par-
ticular, UPC was higher in dogs with MPGN than in
dogs with FSGS I (P = 0.035) and urine specific gravity
was higher in dogs with MixGN than in dogs with
AMY, FSGS I, and FSGS II (P = 0.034, P = 0.008,
and P = 0.043, respectively).
Significant differences among morphological diag-
noses were not detected for the remaining variables
(Tables S1-S2).
Disease Categories
By LM, 64 (39.5%) RBs were diagnosed as non-
ICGN, 57 (35.2%) as ICGN, and 41 (25.3%) as RL-
NOS. By TEM, the final diagnosis changed in 46 dogs;
overall, 82 (50.6%) dogs had ICGN, 59 (36.4%) non-
ICGN, and 21 (13%) RL-NOS. In particular, the final
diagnosis changed for 21 (32.8%) dogs diagnosed as
non-ICGN, 2 (3.5%) diagnosed as ICGN, and 23 (56.1)
diagnosed as RL-NOS based on the LM results, respec-
tively. Cohen’s kappa between LM and TEM was
0.560.
The median age in dogs diagnosed with ICGN
was 70 months, 90 months for dogs with non-
ICGN, and 27 months for dogs with RL-NOS. A
significant difference was found among the 3 disease
categories (P = 0.000). In particular, dogs with RL-
NOS were younger than dogs with ICGN
(P = 0.001) and non-ICGN (P = 0.000), whereas
dogs with ICGN and non-ICGN were of compara-
ble age (Table 4).
Considering the historical information, significant dif-
ferences among groups were found for the detection of
previous UTI (P = 0.035), presence of ascites
(P = 0.040), and hypoalbuminemia (P = 0.006;
Table 5). Overall, previous UTI was less frequent in
dogs with ICGN. Ascites was more common in dogs
with ICGN, whereas hypoalbuminemia was rarely iden-
tified in dogs with RL-NOS.
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With regard to recent biochemical data, significant
differences among groups were found for alterations in
serum concentrations of albumin, total protein, and cal-
cium (P = 0.003, P = 0.019, and P = 0.050, respectively;
Table 5). Hypoalbuminemia and hypoproteinemia were
more common in dogs with ICGN. Hypocalcemia was
more common in dogs with ICGN and hypercalcemia
in dogs with RL-NOS. Significant differences in serum
concentrations of albumin (P = 0.000), urea nitrogen
(P = 0.022), and phosphorus (P = 0.003) were present
Fig 1. Histological and ultrastructural findings in cases of FSGS I (A, B), MGN (C, D), MPGN (E, F), and AMY (G, H). Periodic acid-
Schiff (PAS) section of a glomerulus with a segment of the tuft effaced by mesangial sclerosis (A). Electron microscopy reveals thickened
GBM and increased mesangial matrix. Immune deposits are not identified (B). PAS section of a glomerulus shows remodeling of the
glomerular basement membrane and podocyte hypertrophy (C). Electron microscopy reveals immune complexes (IC) (arrows) in the subep-
ithelial side of the capillary walls (D). PAS section of a glomerulus characterized by global endocapillary and mesangial hypercellularity.
Double contours and thickening of the GBM are observed (E). Electron microscopy reveals IC (arrow) in mesangial and paramesangial
regions of the glomerulus (F). PAS section of a glomerulus characterized by pale pink fibrils expanding the mesangial zones (G). Electron
microscopy shows expansion of 1 glomerular capillary (arrow) by haphazardly arranged fibrils (H). Scale bar for histological
figures = 50 lm.
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among the 3 disease categories (Table 4). In particular,
serum albumin concentration was lower in dogs with
ICGN compared to those with non-ICGN (P = 0.006)
or RL-NOS (P = 0.000), urea nitrogen concentration
was significantly higher in dogs with ICGN than in
those with non-ICGN (P = 0.008), and serum phospho-
rus concentration was significantly higher in dogs with
RL-NOS than in those with non-ICGN (P = 0.001).
Considering urinalysis, significant differences in pro-
portions among groups were found for the presence of
erythrocytes (P = 0.015) and proteinuria (P = 0.035;
Table 5). A finding of >10 erythrocytes/high-power field
was more common in the urine of dogs with ICGN
compared with the other 2 disease categories. Protein-
uria was slightly less frequent in RL-NOS dogs than in
the other 2 disease categories. Mean UPC was higher in
ICGN dogs than in non-ICGN (P = 0.002) and RL-
NOS (P = 0.000) dogs (Table 4).
No significant differences among disease categories
were detected for the remaining variables (Tables S3-
S4).
Because it is perceived by pathologists that AMY and
FSGS I are relatively easy to differentiate from any
ICGN, further analysis was performed to compare the
2 morphological diagnoses to the whole group of
ICGN. In particular, it was found that dogs with AMY
were less likely to be anemic than those with ICGN
(P = 0.038; Tables S1 and S3, respectively), had higher
mean hematocrit values (P = 0.049; Tables S2 and S4,
respectively), and had lower mean urine specific gravity
(P = 0.047; Tables 2 and 4, respectively). Dogs with
FSGS I were more commonly reported to have previous
UTI than were those with ICGN (P = 0.018; Tables 3
and 5, respectively) and less commonly had decreased
serum albumin concentration (P = 0.002; Tables 3 and
5, respectively) and total proteins (P = 0.006; Tables 3
and 5, respectively). In addition, dogs with FSGS I,
compared to those with ICGN, had higher serum con-
centrations of albumin (P = 0.000; Tables 2 and 4,
respectively) and total protein (P = 0.039; Tables 2 and
S4, respectively) and lower UPC (P = 0.002; Tables 2
and 4, respectively). Finally, dogs with FSGS I, com-
pared to those with ICGN, less frequently had hema-
turia (P = 0.000; Tables 3 and 5, respectively).
Discussion
We analyzed the clinical, laboratory, and pathological
data of 162 canine RBs examined at the EVRPS
between 2008 and 2015. The number of RBs submitted
has increased consistently over the 7-year period (9%
per year), likely as a result of increasing awareness of
the service by European veterinarians, the recent publi-
cation on RB indications, and new criteria to diagnose
renal diseases in dogs.
Interestingly, when examining the geographical origin
of the veterinarians using the service, RBs from the
North European countries were overrepresented, possi-
bly causing a bias in the distribution of renal diseases.
Indeed, northern countries are not endemic for leishma-
niasis, which is a major cause of ICGN in dogs from
southern Europe.6,7 However, the proportion of dogs
with ICGN in our case series (50.6%) was consistent
with that of a recent investigation (48.1%), confirming
that approximately half of the renal diseases in dogs are
immune-mediated in origin.1
In our series, the agreement between LM and TEM
diagnosis for either morphological diagnoses or disease
categories was only moderate. Hence, our results
emphasize the importance of TEM in the diagnostic
evaluation of RBs because this tool can identify lesions
that would go undetected by LM. Identification of
Table 1. Morphological diagnosis of 162 canine renal biopsies according to light microscopy and subsequent
transmission electron microscopic analysis.
LM Morphological
diagnosis (N)
LM Morphological
diagnosis confirmed by TEM (%)
LM Morphological diagnosis
changed by TEM (%) List of modified morphological diagnosis (N; %)
MGN (28) 12 (42.9%) 16 (57.1%) MPGN (1; 3.6%); MixGN (11; 39.3%);
FSGS II (2; 7.1%); MCD (1; 3.6%);
FSGS I (1; 3.6%)
MPGN (26) 21 (80.8%) 5 (19.2%) MGN (1; 3.8%); MixGN (4; 15.4%)
MixGN (2) 2 (100%) 0 (0%) –
MCD (1) 1 (100%) 0 (0%) –
AMY (11) 11 (100%) 0 (0%) –
FSGS I (53) 31 (58.5%) 22 (41.5%) MPGN (7; 13.2%); MixGN (1; 1.9%);
FSGS II (11; 20.8%); JN (3; 5.7%)
JN (4) 4 (100%) 0 (0%)
MD (21) 6 (28.6%) 15 (71.4%) MPGN (1; 4.8%); MixGN (1; 4.8%);
FSGS II (2; 9.5%); MCD (5; 23.8%);
FSGS I (4; 19.0%); JN (2; 9.5%)
No lesions (16) 3 (18.8%) 13 (81.2%) MPGN (1; 6.3%); FSGS II (4; 25.0%);
MCD (5; 31.3%); MD (3; 18.8%)
LM, light microscopy; TEM, transmission electron microscopy; MGN, membranous glomerulonephritis; MPGN, membranoproliferative
glomerulonephritis; MixGN, mixed glomerulonephritis; FSGS II, secondary focal and segmental glomerulosclerosis; MCD, minimal change
disease; AMY, amyloidosis; FSGS I, primary focal and segmental glomerulosclerosis; JN, juvenile nephropathies; MD, miscellaneous dis-
eases.
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immune complexes is necessary for proper classification
of renal diseases, and the combined use of LM and
TEM allowed us to localize them within the glomerulus
and to achieve the final morphological diagnosis. Fur-
thermore, our study confirms the necessity of evaluating
RBs with both LM and TEM in FSGS cases, because
LM alone cannot differentiate between primary podo-
cyte injury (possibly genetic) and deposition of immune
complexes.8,9
When considering cases divided according to disease
categories, dogs with RL-NOS were significantly
younger compared to dogs with ICGN and non-
ICGN. This finding was mainly related to the high fre-
quency of JN in this disease category, which is a major
cause of chronic kidney disease in young pure breed
dogs.10,11 In contrast to age, sex was similarly
distributed among disease categories or morphological
diagnoses.
Concerning history, differences were documented for
UTI, being less frequent in dogs with ICGN than in
those with non-ICGN or RL-NOS. Dogs with UTI
may develop renal disease due to bacterial invasion of
the kidneys. In this setting, the pathogenesis of kidney
damage is not expected to be associated with deposi-
tion of immune complexes but, depending on the distri-
bution of bacteria or binding affinity of their toxins,
with direct tubular or glomerular lesions, possibly lead-
ing to non-ICGN.12 Indeed, the majority of dogs with
a morphological diagnosis of MCD and FSGS I (i.e,
non-ICGN) had a history of UTI. Conversely, UTI
was reported in <10% of dogs with MPGN and
MixGN (i.e, ICGN). Whether bacteria triggered the
Table 3. Distribution of 162 dogs with kidney disease according to morphological diagnoses based on electron
microscopy and different categorical variables. Only variables with significantly different proportions among morpho-
logical diagnoses are shown.
Morphological diagnosis [n (%)]
MGN MPGN MixGN FSGS II MCD AMY FSGS I JN MD No lesions
History
Urinary tract infections
Yes 2 (33.3) 1 (9.1) 1 (9.1) 4 (57.1) 3 (75.0) 2 (28.6) 8 (61.5) 3 (60.0) 1 (25.0) 1 (100.0)
No 4 (66.7) 10 (90.9) 10 (90.9) 3 (42.9) 1 (25.0) 5 (71.4) 5 (38.5) 2 (40.0) 3 (75.0) 0 (0.0)
Ascites
Yes 6 (75.0) 3 (20.0) 6 (50.0) 0 (0.0) 0 (0.0) 1 (16.7) 1 (9.1) 0 (0.0) 1 (33.3) 0 (0.0)
No 2 (25.0) 12 (80.0) 6 (50.0) 5 (100.0) 4 (100.0) 5 (83.3) 10 (90.9) 4 (100.0) 2 (67.7) 1 (100.0)
Hematology
Leukocytes count
Decreased 0 (0.0) 3 (23.1) 3 (33.3) 0 (0.0) 0 (0.0) 1 (12.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Normal 8 (100.0) 9 (69.2) 6 (66.7) 6 (85.7) 1 (33.3) 6 (75.0) 10 (100.0) 3 (100.0) 1 (50.0) 0 (0.0)
Increased 0 (0.0) 1 (7.7) 0 (0.0) 1 (14.3) 2 (66.7) 1 (12.5) 0 (0.0) 0 (0.0) 1 (50.0) 0 (0.0)
Biochemistry
Albumin concentration
Decreased 11 (91.7) 18 (69.2) 13 (81.3) 4 (26.7) 1 (16.7) 9 (100.0) 7 (29.2) 0 (0.0) 1 (20.0) 1 (50.0)
Normal 1 (8.3) 8 (30.8) 3 (18.7) 9 (60.0) 3 (50.0) 0 (0.0) 17 (70.8) 6 (85.7) 3 (60.0) 1 (50.0)
Increased 0 (0.0) 0 (0.0) 0 (0.0) 2 (13.3) 2 (33.3) 0 (0.0) 0 (0.0) 1 (14.3) 1 (20.0) 0 (0.0)
Total proteins concentration
Decreased 9 (75.0) 12 (48.0) 10 (66.7) 3 (20.0) 1 (20.0) 8 (88.9) 4 (19.0) 1 (14.3) 0 (0.0) 1 (50.0)
Normal 3 (25.0) 12 (48.0) 4 (26.7) 9 (60.0) 4 (80.0) 1 (11.1) 17 (81.0) 0 (0.0) 4 (100.0) 1 (50.0)
Increased 0 (0.0) 1 (4.0) 1 (6.6) 3 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (85.7) 0 (0.0) 0 (0.0)
Urinalysis
Urine color
Normal 6 (100.0) 16 (100.0) 8 (100.0) 8 (100.0) 4 (100.0) 7 (100.0) 14 (100.0) 3 (100.0) 3 (75.0) 2 (100.0)
Light 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0)
Dark 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Glycosuria
Yes 2 (20.0) 0 (0.0) 1 (8.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (14.3) 1 (25.0) 1 (33.3)
No 8 (80.0) 25 (100.0) 11 (91.7) 17 (100.0) 6 (100.0) 8 (100.0) 24 (100.0) 6 (85.7) 3 (75.0) 2 (66.7)
Erythrocytes (n/hpfl)
No 0 (0.0) 3 (20.0) 0 (0.0) 0 (0.0) 1 (33.3) 0 (0.0) 11 (68.8) 0 (0.0) 0 (0.0) 1 (33.3)
<10 6 (100.0) 9 (60.0) 6 (66.7) 5 (83.3) 1 (33.3) 7 (87.5) 4 (25.0) 2 (66.7) 1 (100) 1 (33.3)
>10 0 (0.0) 3 (20.0) 3 (33.3) 1 (16.7) 1 (33.3) 1 (12.5) 1 (6.2) 1 (33.3) 0 (0.0) 1 (33.3)
Proteinuria
Yes 13 (100.0) 27 (100.0) 17 (100.0) 14 (82.4) 6 (85.7) 9 (100.0) 32 (100.0) 4 (57.1) 7 (100.0) 3 (100.0)
No 0 (0.0) 0 (0.0) 0 (0.0) 3 (17.6) 1 (14.3) 0 (0.0) 0 (0.0) 3 (42.9) 0 (0.0) 0 (0.0)
MGN, membranous glomerulonephritis; MPGN, membranoproliferative glomerulonephritis; MixGN, mixed glomerulonephritis; FSGS
II, secondary focal and segmental glomerulosclerosis; MCD, minimal change disease; AMY, amyloidosis; FSGS I, primary focal and seg-
mental glomerulosclerosis; JN, juvenile nephropathies; MD, miscellaneous diseases; hpf, high-power field.
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development of MCD and FSGS I or were the conse-
quence cannot be answered. The reason why dogs with
RL-NOS were more likely to have UTI as compared to
those with ICGN is likely a consequence of the fact
that some of the dogs within the former disease cate-
gory had JN, which has been shown to predispose to
UTI.13
With regard to urinalysis, proteinuria was more fre-
quent in dogs with ICGN or non-ICGN than in those
with RL-NOS, although significance was small. How-
ever, the overall magnitude of proteinuria in dogs with
ICGN was 2-fold and 3-fold higher than in those with
non-ICGN and RL-NOS, respectively. The more severe
proteinuria observed in dogs with ICGN explained the
fact that on the biochemical profile, hypoalbuminemia
was more common, in comparison with the other
groups. The marked hypoalbuminemia, in turn,
accounted for the more frequently documented
hypoproteinemia and hypocalcemia as well as the more
common ascites reported in dogs with ICGN. Hence,
protein-losing nephropathies due to immune-complex
deposition may cause larger alterations in the permse-
lectivity of the glomerular capillary wall than those
caused either by non-ICGN or by RL-NOS in dogs.
Although dogs with non-ICGN had proteinuria
slightly more commonly than those with RL-NOS,
the degree of severity did not differ. As expected, the
biochemical profile showed no differences in serum
albumin concentrations between the 2 groups and the
frequency of hypoproteinemia, hypocalcemia, and
ascites also was similar. The suspected larger permse-
lectivity of glomeruli in dogs with ICGN might also
explain the more frequent hematuria observed in this
disease category.
Notably, from a clinical standpoint, differentiation of
dogs with 1 or the other disease category based on the
extent of proteinuria was not possible due to the fact
that there was large overlap among the 3 disease cate-
gories. However, in our series none with non-ICGN
and RL-NOS dogs had UPC >12.5, whereas 21.1% of
those with ICGN had UPC >12.5 (data not shown).
Although dogs with renal proteinuria above this thresh-
old might be more likely to have a nephropathy with an
immune-complex pathogenesis, in our experience dogs
with AMY also can have very high UPC. Among mor-
phological diagnoses of ICGN, dogs with MPGN had
the most severe proteinuria. However, differentiating
dogs with the different forms of ICGN based on the
extent of proteinuria was not possible. Unexpectedly,
approximately 10% of dogs with FSGS II had no pro-
teinuria. The absence of proteinuria in a disease charac-
terized by glomerular deposition of immune complexes
might suggest that in some affected dogs, increased
tubular reabsorption capacity was present that compen-
sated for the protein loss. Alternatively, the sclerosis
might indicate that an improvement of glomerular
lesions has occurred.14,15 Unfortunately, it was
unknown whether dogs were receiving any medication
at the time of RB. Similarly to ICGN, it was not feasi-
ble to differentiate morphological diagnoses between
dogs with non-ICGN and RL-NOS. Also, dogs with
AMY (i.e, non-ICGN), which frequently is associated
with severe proteinuria, had protein loss that over-
lapped with dogs affected by other non-ICGN.16
The biochemical profile of dogs with ICGN showed
higher serum urea nitrogen concentrations, but not
serum creatinine concentration. This difference was
observed in dogs with non-ICGN and not those with
Table 4. Mean values of different variables in 162 dogs with kidney disease, according to disease category based on
electron microscopy. Only variables with significant differences among disease categories are shown.
Disease Category
Mean  standard deviation
(median; min–max)
[N]
ICGN Non-ICGN RL-NOS Total
Age (months) 72.8  35.7
(70; 1–143)
[79]
87.4  36.9
(90; 14–165)
[55]
40.1  33.0
(27; 3–103)
[19]
74.0  38.4
(74; 1–165)
[153]
Serum albumin concentration (g/L) 20.10  6.92
(19.45; 10.0–37.0)
[69]
24.01  7.38
(23.30; 7.0–38.0)
[39]
27.99  5.36
(28.95; 18.0–37.0)
[14]
22.25  7.38
(22.00; 7.0–38.2)
[122]
Serum urea nitrogen concentration (mmol/L) 16.54  12.20
(11.90; 1.7–43.2)
[48]
9.86  9.67
(7.30; 1.2–51.8)
[28]
22.03  31.63
(13.90; 1.0–105.0)
[9]
14.92  14.97
(11.30; 1.0–105.0)
[85]
Serum phosphorus concentration (mmol/L) 1.86  0.83
(1.60; 0.4–4.6)
[63]
1.62  0.86
(1.41; 0.8–6.0)
[34]
3.24  3.03
(2.18; 0.9–12.5)
[14]
1.96  1.40
(1.56; 0.4–12.5)
[111]
UPC 9.28  10.05
(6.47; 0.20–69.00)
[71]
4.73  2.82
(4.60; 1.05–12.00)
[45]
2.98  3.28
(2.00; 0.06–12.23)
[14]
7.02  8.06
(5.04; 0.06–69.00)
[130]
ICGN, immune-complex-mediated glomerulonephritis; non-ICGN, non-immune-complex-mediated glomerulonephritis; RL-NOS, renal
lesions not otherwise specified; UPC, urine protein-to-creatinine ratio.
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RL-NOS. This observation might be partly explained
by an increment in the protein catabolism to counteract
the lower oncotic pressure linked to hypoalbuminemia
in dogs with ICGN. With regard to serum creatinine
concentration, dogs with MCD had lower concentra-
tions than did those with MPGN. In several studies,
increases in serum creatinine concentration correlated
more with tubulo-interstitial than glomerular dam-
age.17,18 Minimal change disease is by definition charac-
terized by normal glomeruli on LM, and lesions are
detected only by TEM. In contrast, MPGN can have
variable involvement of the tubulo-interstitium and
associated histological changes. The absence of tubulo-
interstitial damage in MCD in this particular case can,
at least partially, explain why serum creatinine
concentration was lower compared to concentrations in
dogs with MPGN.
Furthermore, the biochemical profile showed that
dogs with RL-NOS were more likely to have hypercal-
cemia and hyperphosphatemia. Increased concentrations
of phosphorus and, less often, of calcium are observed
if glomerular filtration rate is severely impaired. How-
ever, serum creatinine concentrations did not differ
among the 3 disease categories, suggesting that the esti-
mated extent of renal dysfunction probably was not
responsible for these results. Because dogs with RL-
NOS included some with JN, which might be diagnosed
at a young age, it is possible that hypercalcemia and
hyperphosphatemia were associated with physiologic
growth. Indeed, among dogs with RL-NOS, 25% were
<1 year old (data not shown).
Because AMY is relatively easy to diagnose by LM
and Congo red staining and FSGS I still represents a
diagnostic conundrum, we decided to compare the 2
morphological diagnoses with the entire group of
ICGN. Anemia was less frequent in dogs with AMY,
and their urine was less concentrated. The reason for
the former observation is elusive, whereas the latter
might be explained by the fact that amyloid deposits
may be often observed also in the medulla, possibly
decreasing the hypertonicity of this compartment and,
in turn, water reabsorption.19 In dogs with FSGS I,
hypoalbuminemia and hypoproteinemia as well as pro-
teinuria and hematuria were less marked than in the
entire group of ICGN; these results are consistent with
the above differences observed between ICGN and the
entire group of non-ICGN.
One limitation of our study is the lack of IF data.
Indeed, IF integrated with LM and TEM may help bet-
ter characterize glomerulonephritis in dogs, further
refining the morphological diagnosis. Another relevant
limitation is represented by the fact that different labo-
ratories performed blood testing and urinalysis, with
reference ranges that might have differed. However, the
potential bias probably was evenly distributed among
disease categories and morphological diagnoses,
decreasing its confounding effect.
In conclusion, our study provides useful information
about the frequency of renal diseases in dogs across
Europe, with ICGN and non-ICGN representing almost
90% of the RBs. From a clinical perspective, dogs with
ICGN, in particular those with MPGN, had more sev-
ere proteinuria than did those with non-ICGN or RL-
NOS, leading to more severe hypoalbuminemia. Clinical
and laboratory differentiation among dogs with the dif-
ferent morphological diagnoses and among dogs with
different disease categories was difficult due to overlap-
ping results. Based on our results, RBs examined by
LM and TEM are recommended to allocate dogs with
renal lesions to specific morphological diagnoses and
disease categories.
Table 5. Distribution of 162 dogs with kidney disease
according to disease category based on electron micro-
scopy and different categorical variables. Only variables
with significantly different proportions among disease
categories are shown.
Disease category [n (%)]
ICGN Non-ICGN RL-NOS Total
History
Urinary tract infections
Yes 8 (22.9) 13 (54.2) 5 (50.0) 26 (37.7)
No 27 (77.1) 11 (45.8) 5 (50.0) 43 (62.3)
Ascites
Yes 15 (37.5) 2 (9.5) 1 (12.5) 18 (26.1)
No 25 (62.5) 19 (90.5) 7 (87.5) 51 (73.9)
Hypoalbuminemia
Yes 23 (100) 16 (94.1) 1 (50.0) 40 (95.2)
No 0 (0.0) 1 (5.9) 1 (50.0) 2 (4.8)
Biochemistry
Albumin concentration
Decreased 46 (66.7) 17 (43.6) 2 (14.3) 65 (53.3)
Normal 21 (30.4) 20 (51.3) 10 (71.4) 51 (41.8)
Increased 2 (2.9) 2 (5.1) 2 (14.3) 6 (4.9)
Total proteins concentration
Decreased 34 (50.7) 13 (37.1) 2 (15.4) 49 (42.6)
Normal 28 (41.8) 22 (62.9) 11 (84.6) 61 (53)
Increased 5 (7.5) 0 (0.0) 0 (0.0) 5 (4.3)
Calcium concentration
Decreased 22 (36.7) 9 (25.7) 3 (23.1) 34 (31.5)
Normal 35 (58.3) 23 (65.7) 6 (46.2) 64 (59.3)
Increased 3 (5.0) 3 (8.6) 4 (30.8) 10 (9.3)
Urinalysis
Urine color
Normal 38 (100) 25 (100) 8 (88.9) 71 (98.6)
Light 0 (0.0) 0 (0.0) 1 (11.1) 1 (1.4)
Dark 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Glycosuria
Yes 3 (4.7) 0 (0.0) 3 (21.4) 6 (5.2)
No 61 (95.3) 38 (100) 11 (78.6) 110 (94.8)
Erythrocytes (n/hpf)
No 3 (8.3) 12 (44.4) 1 (14.3) 16 (22.9)
<10 26 (72.2) 12 (44.4) 4 (57.1) 42 (60.0)
>10 7 (19.4) 3 (11.1) 2 (28.6) 12 (17.1)
Proteinuria
Yes 71 (95.9) 47 (97.9) 14 (82.4) 132 (95.0)
No 3 (4.1) 1 (2.1) 3 (17.6) 7 (5.0)
ICGN, immune-complex-mediated glomerulonephritis; non-
ICGN, non-immune-complex-mediated glomerulonephritis; RL-
NOS, renal lesions not otherwise specified; hpf, high-power field.
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